Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin-A for Bruxism Assessed by Digital Occlusal Analysis
NCT07640035Phase 1Not yet recruiting
- Sponsor
- Bilecik Şeyh Edebali University
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial in bruxism comparing Botulinum Toxin-A Group with Placebo Group (2 arms). Primary endpoints: Maximum Bite Force at 6 months, Right/Left Occlusal Force Balance at 6 months and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
bruxism
Beyond the preview
Go deeper on NCT07640035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640035.